Table 3 Safety of AABO and UAE
AABO group (n = 34) | UAE group (n = 34) | P | |
|---|---|---|---|
Any adverse events, n (%) | 2 (5.9) | 20 (58.8) | < 0.001 |
Serious adverse events, n (%) | 0 | 0 | |
Post-embolization syndrome, n (%) | 1 (2.9) | 16 (47.1) | |
Abdominal pain | 0 | 2 (5.9) | |
Hip pain | 0 | 10 (29.4) | |
Fever | 1 (2.9) | 2 (5.9) | |
Nausea and vomiting | 0 | 2 (5.9) | |
Decreased menstruation, n (%) | 1 (2.9) | 4 (11.8) | |
Amenorrhea, n (%) | 0 | 0 |